BioNTech SE
NASDAQBNTX downgraded by BMO Capital to Market Perform from Outperform, price target cut to $105 from $128 (-18%), now trading below revised PT at $103.76.
Snapshot as of 20 Sept 2026
BNTX heads into the back half of August with analysts trimming targets yet options traders quietly turning more constructive — a split that makes the current setup worth examining closely. The options picture is the…
BNTX delivered its Q2 results on August 4 and the market's verdict was swift — the stock slipped roughly 1% on the day and has now shed 6% over the past month, with analysts moving quickly to pare back their price…
BNTX heads into its August 4 earnings report with options sentiment shifting more constructive than it has been in months, even as the stock sits roughly flat on the week at $92.45. The clearest change in positioning…
BNTX heads into the week with a fresh analyst target cut from its most prominent sell-side backer — yet the options market is, unusually, leaning more bullish than it has in months. Morgan Stanley's Terence Flynn…
BNTX heads into the final weeks before its August 4 earnings print with analyst sentiment firmly positive, short sellers retreating, and options traders less defensive than they've been all year. The most interesting…
BNTX arrives at its May 15 earnings date with the stock nursing a 6.4% weekly loss, analysts trimming targets, yet a Street consensus that remains broadly constructive — the question is whether the pipeline can justify…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BNTX — free to start on ORTEX.
Sign up for free →Open BNTX on ORTEX